Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results
July 29 2022 - 7:30AM
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel cell and gene therapies and vaccines, today
announced that it will host a conference call and simultaneuous
webcast to discuss the Company’s second quarter 2022 financial
results and provide a business update at 8:30 a.m. ET on Friday,
August 5, 2022.
Ocugen will issue a pre-market earnings announcement on the same
day. Attendees are invited to participate on the call using the
following details:
Dial-in Numbers: (800) 715-9871 for U.S.
callers and (646) 307-1963 for international callers
Conference ID: 7036957Webcast:
Available on the events section of the Ocugen investor site
A replay of the call and archived webcast will be available for
approximately 45 days following the event on the Ocugen investor
site.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines that
improve health and offer hope for patients across the globe. We are
making an impact on patient’s lives through courageous
innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene
therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on Twitter and LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations, such as market and other
conditions. These and other risks and uncertainties are more fully
described in our periodic filings with the Securities and Exchange
Commission (the “SEC”), including the risk factors described in the
section entitled “Risk Factors” in the quarterly and annual reports
that we file with the SEC. Any forward-looking statements that we
make in this press release speak only as of the date of this press
release. Except as required by law, we assume no obligation to
update forward-looking statements contained in this press release
whether as a result of new information, future events or otherwise,
after the date of this press release.
Contacts:Tiffany HamiltonHead of
CommunicationsIR@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024